Reduction of myocardial dysfunction with erythropoietin (EPO) in ischemic/reperfusion neonatal model

• Grant number: 10/01854-5
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date: May 01, 2010
• End date: January 31, 2011
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Orlando Petrucci Jr
• Grantee: Daise Nunes Queiroz da Cunha
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

The low cardiac output syndrome is multifactorial, however the ischemic andreperfusion injury are inevitable during intra cardiac defects repair and it hasimportant role on it. The identification of new myocardium protective strategies mightreduce the incidence of low cardiac output syndrome with less mortality andmorbidity. The erythropoietin (EPO) has direct cardioprotective effects in several invivo and in vitro studies. We have not information in the literature of studies using alarger animals and immature myocardium. The main objective of this study isassessing the favorable EPO myocardium effects in clinically relevantischemic/reperfusion model using neonatal piglets. This study is a prelude of futureclinical studies. To test this hypothesis we will use sophisticated systolic and diastolicmyocardium indexes. In addition, we will assess the RISK pathway activation andapoptosis results with EPO administration.